Page 194 - rcv31n3.vp

Actualización en medicamentos antidiabéticos y riesgo cardiovascular Revista Uruguaya de Cardiología
María del Pilar Serra Sansone Volumen 31 | nº 3 | Diciembre 2016

8. Anand SS, Dagenais GR, Mohan V, Diaz R, Trial In macro- Vascular Events): a randomised con-
Probstfield J, Freeman R, et al; EpiDREAM trolled trial. Lancet 2005; 366(9493):1279-89.
Investigators. Glucose levels are associated with car-
18. ACCORD Study Group; Gerstein HC, Miller ME,
diovascular disease and death in an international
Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, et
cohort of normal glycaemic and dysglycaemic men and
al. Long-term effects of intensive glucose lowering on
women: the EpiDREAM cohort study. Eur J Prev Car-
cardiovascular outcomes. N Engl J Med 2011;
diol 2012; 19(4):755-64.
364(9):818-28.
9. Selvin E, Marinopoulos S, Berkenblit G, Rami T,
19. ADVANCE Collaborative Group; Patel A, Mac-
Brancati FL, Powe NR, et al. Meta-analysis:
MahonS,ChalmersJ,NealB,BillotL,Wood-
glycosylated hemoglobin and cardiovascular disease in
ward M, et al. Intensivebloodglucosecontrolandvas-
diabetes mellitus. Ann Intern Med 2004;
cular outcomes in patients with type 2 diabetes. N Engl
141(6):421-31.
J Med 2008; 358(24):2560-72.
10. Gerstein HC, Islam S, Anand S, Almahmeed W,
20. Duckworth W, Abraira C, Moritz T, Reda D,
DamascenoA,DansA,etal. Dysglycaemia and the
Emanuele N, Reaven PD, et al; VADT Investiga-
risk of acute myocardial infarction in multiple ethnic
tors. Glucose control and vascular complications in ve-
groups: an analysis of 15,780 patients from the
terans with type 2 diabetes. N Engl J Med 2009;
INTERHEART study. Diabetologia 2010;
360(2):129-39.
53(12):2509-17.
11. Gerstein HC,Pogue J, Mann JF,LonnE,Dage- 21. Ray KK, Seshasai SR, Wijesuriya S, Sivakuma-
nais GR, McQueen M, et al; HOPE investigators. ran R, Nethercott S, Preiss D, et al. Effect of inten-
The relationship between dysglycaemia and cardiovas- sive control of glucose on cardiovascular outcomes and
cular and renal risk in diabetic and non-diabetic parti- death in patients with diabetes mellitus: a meta-analy-
cipants in the HOPE study: a prospective epidemiologi- sis of randomised controlled trials. Lancet 2009;
cal analysis. Diabetologia 2005; 48(9):1749-55. 373(9677):1765-72.
12. Stratton IM, Adler AI, Neil HA, Matthews DR, 22. Authors/Task Force Members; Rydén L, Grant
Manley SE, Cull CA, et al. Association of glycaemia PJ, Anker SD, Berne C, Cosentino F, Danchin N,
with macrovascular and microvascular complications et al; ESC Committee for Practice Guideli-
of type 2 diabetes (UKPDS 35): prospective observatio- nes(CPG). ESC Guidelines on diabetes, pre-diabetes,
nal study. BMJ 2000; 321(7258):405-12. and cardiovascular diseases developed in collaboration
with the EASD: the Task Force on diabetes, pre-diabe-
13. The Diabetes Control and Complications Trial tes, and cardiovascular diseases of the European So-
Research Group. The effect of intensive treatment of ciety of Cardiology (ESC) and developed in collabora-
diabetes on the development and progression of tion with the European Association for the Study of
long-term complications in insulin-dependent diabetes Diabetes(EASD).EurHeartJ2013;34(39):3035-87.
mellitus. N Engl J Med 1993; 329(14):977-86.
23. Rydén L, Shahim B, Mellbin L. Clinical implica-
14. Nathan DM, Cleary PA, Backlund JY, Genuth tions of cardiovascular outcome trials in Type 2 diabe-
SM, Lachin JM, Orchard TJ, et al; Diabetes Con- tes: from DCCT to EMPA-REG. Clin Ther 2016;
trol and Complications Trial/Epidemiology of 38(6):1279-87.
Diabetes Interventions and Complications
(DCCT/EDIC) Study Research Group. Intensive 24. Nissen SE, Wolski K. Effect of rosiglitazone on the
diabetes treatment and cardiovascular disease in pa- risk of myocardial infarction and death from cardiovas-
tients with type 1 diabetes. N Engl J Med 2005; cular causes. N Engl J Med 2007; 356(24): 2457-71.
353(25):2643-53.
25. Food and Drug Administration. FDA news release:
15. UK Prospective Diabetes Study (UKPDS) FDA Announces new recommendations on evaluating
Group. Intensive blood-glucose control with sulp- cardiovascular risk in drugs intended to treat Type 2
honylureas or insulin compared with conventional diabetes.December 17, 2008. Silver Spring, MD: FDA,
treatment and risk of complications in patients with 2008. Disponible en: http://www.fda.gov/News-
type 2 diabetes (UKPDS 33). Lancet 1998; Events/Newsroom/PressAnnounce-
352(9131):837-53. ments/2008/ucm116994.htm.[Consulta:7julio2016].
16. Holman RR, Paul SK, Bethel MA, Matthews DR, 26. Nauck MA, Del Prato S, Gerstein HC, Leiter LA.
Neil HA. 10-year follow-upof intensive glucose control Diabetes treatments to reduce cardiovascular events in
in type 2 diabetes. N Engl J Med 2008; diabetes Type 2. Medscape CME released: 2/1/2016.
359(15):1577-89. Disponible en:http://www.medscape.org/ viewarti-
cle/857854. [Consulta: 7 julio 2016].
17. Dormandy JA,Charbonnel B,Eckland DJ,
Erdmann E, Massi-Benedetti M, Moules IK, et al. 27. American Diabetes Association. Approaches to
Secondaryevents inpatients withtype 2 diabetes inthe glycemic treatment. Diabetes Care 2016; 39(Suppl
PROactive Study (PROspective pioglitAzone Clinical 1):S52-9.
538